scispace - formally typeset
C

Charles Pyke

Researcher at Novo Nordisk

Publications -  75
Citations -  7756

Charles Pyke is an academic researcher from Novo Nordisk. The author has contributed to research in topics: Stromal cell & Cancer. The author has an hindex of 37, co-authored 69 publications receiving 6946 citations. Previous affiliations of Charles Pyke include University of California, San Francisco & Finsen Laboratory.

Papers
More filters
Journal ArticleDOI

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

TL;DR: Results give important new insight into the molecular mode of action of GLP-1 analogs by identifying the exact cellular localization of GLp-1R.
Journal ArticleDOI

Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways.

TL;DR: The data support the hypothesis that there are at least two distinct phases of involution: an initial phase, characterized by induction of the apoptosis-associated genes SGP-2 and ICE and apoptosis of fully differentiated mammary epithelial cells without visible degradation of the extracellular matrix, and a second phase, characterize by extrace cellular matrix remodeling and altered mesenchymal-epithelial interactions, followed by apoptotic cells that are losing differentiated functions.
Journal Article

Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

TL;DR: Results support the view that components of the plasminogen activation system may act to influence proteolytic events occurring at the interface between stroma and malignant cells in adenocarcinomas of the colon in humans.
Journal Article

Laminin-5 Is a Marker of Invading Cancer Cells in Some Human Carcinomas and Is Coexpressed with the Receptor for Urokinase Plasminogen Activator in Budding Cancer Cells in Colon Adenocarcinomas

TL;DR: The colocalization of laminin-5 and urokinase-type plasminogen activator receptor in a subset of cancer cells in colon cancer suggests that a controlled up-regulation of a number of gene products is a characteristic of budding colon cancer cells, and that these gene products serve functions crucial for the invasive phenotype of these cancer cells.